Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon lambda dose-ranging monotherapy study in interferon-naive HBeAg-positive chronic hepatitis B
NL-OMON39072Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of peginterferon lambda-1a in Chronic Hepatitis B (CHB) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: HBeAg seroconversion at Week 72 and Serious adverse events and discontinuations due to adverse events. Started Aug 2011; status: active, not recruiting.
02
Drugs
peginterferon lambda-1a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON39072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39072.